Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Trametinib

Catalog No: tcsc0060

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Specifications

CAS No:
871700-17-3

Formula:
$C_{26}H_{23}FIN_5O_4$

Pathway:
MAPK/ERK Pathway

Target:
MEK

Purity / Grade:
>98%

Solubility:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

DMSO : 33.33 mg/mL (54.16 mM; Need ultrasonic)

Alternative Names:
GSK1120212;JTP-74057

Observed Molecular Weight:
615.39

Product Description

Trametinib is a potent **MEK** inhibitor that specifically inhibits MEK1/2, with an **IC_{50}** value of about 2 nM. Due to the poor solubility of Trametinib, **Trametinib DMSO solvate (Cat. No.: HY-10999A)** is the more commonly used form.

IC50 & Target: IC50: 2 nM (MEK1/2)[1]

In Vitro: Trametinib (0.1-100 nM) blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (PBMCs). Trametinib (JTP-74057) inhibits the growth of 9 out of 10 human colorectal cancer cell lines, and they shows cell-cycle arrest at the G1 phase after drug tratment[1]. The combination of GSK2118436 and Trametinib (GSK1120212) effectively inhibits cell growth, decreases ERK phosphorylation, decreases cyclin D1 protein, and increases p27(kip1) protein in the resistant clones[2].

In Vivo: Adjuvant-induced arthritis (AIA) and type II collageninduced arthritis (CIA) development are suppressed almost completely by 0.1 mg/kg of Trametinib (JTP-74057) or 10 mg/kg of Leflunomide[1]. Trametinib (0.3 mg/kg, 1 mg/kg, p.o.) is effective in inhibiting the HT-29 xenograft growth in a nude mouse xenograft model[2].